Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
120
resultados
Última actualización
27/12/2025 [07:05:00]
Resultados 100 a 120 de 120
Resumen de: AU2024234602A1
The present invention is directed to compositions and methods for treating infection with SARS-CoV-2 virus and its sequelae through inhibition of the β-arrestin (arrestin-2) pathway by use of β-adrenergic inverse agonists, particularly including nadolol. The compositions and methods can also employ additional agents to block infection with SARS-CoV-2 virus or inhibit inflammation, particularly inflammation affecting the respiratory tract.
Resumen de: US2025332162A1
The present invention is generally directed to a potent therapy for SARS-CoV-2 (CoV2) disease which may involve combinations of agents. Here we describe combinations of 2, 3 or more drugs wherein the combination inhibits CoV2 replication through one or more mechanisms of action and increases potency of nucleoside and nucleotide analog drugs through inhibition of cellular enzymes involved in purine nucleotide biosynthesis. The combinations may be delivered as individual doses, concurrent dosing, or co-formulation of 2 or more agents. The inventive aspect includes identified components, the ratios among identified components and treatment regimens for reducing morbidity and mortality of CoV2 infection. Further claimed are drug formulations and methods of delivery.
Resumen de: US2025332170A1
Compositions for and methods of treating lung conditions, such as those associated with elevated cytokines, are described. The methods include administration of vandetanib or a pharmaceutically acceptable salt thereof. Methods of treating COVID-19 via administration of vandetanib or a pharmaceutically acceptable salt thereof are also described. Administration of vandetanib can reduce levels of cytokines that are elevated in subjects suffering from COVID-19 and mitigate or eliminate the cytokine storm associated with severe cases of COVID-19.
Resumen de: US2025332220A1
The present invention relates to a method for treating and/or preventing pneumonia, including administering a therapeutically effective amount of cerebral dopamine neurotrophic factor (CDNF) to a subject in need thereof. The pneumonia is caused by infection of influenza A virus or severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
Resumen de: US2025332247A1
The present disclosure provides a glycoengineered SARS-COV-2 spike protein which is capable of eliciting an enhanced immune response relative to a native spike protein of SARS-COV-2 and its variants. The glycoengineered spike protein exposes the glycosylation sites and at the same time preserves the tertiary structure of the spike protein. The present disclosure therefore provides improved immunogens, vaccines, and methods for better prevention and treatment of the emerging coronavirus infections.
Resumen de: US2025332136A1
Described herein is a composition and methods for treating, reducing the symptoms of, or prophylaxis of viral infections, and particularly SARS-CoV-2. The composition enhances delivery of oxygen to the tissues. Also described herein is a composition and methods for treating cancers, particularly, adenocarcinomas, infiltrating ductal adenocarcinoma, metastatic ductal adenocarcinoma, and neuroendocrine tumors. The composition inhibits the growth of tumor cells and promotes cytoreduction of tumors.
Resumen de: EP4640230A1
An application of Shenling Baizhu in the preparation of a medicine for treating neuropsychiatric symptoms of recovered COVID-19 patients.
Resumen de: EP4641196A1
Disclosed is a CRISPR/Cas based system for screening an RNA aptamer against a target protein, comprising: (i) a guide RNA comprising a recognition sequence and a nucleic acid aptamer random library having a predetermined length; (ii) a target sequence complementary to the recognition sequence of the guide RNA; (iii) a selection marker located downstream of the target sequence and comprising a basal promoter and a selection marker gene; (iv) a fusion protein comprising the target protein and a transcriptional activation module, wherein a binding of the target protein to an RNA aptamer of the nucleic acid aptamer random library results in recruitment of the transcriptional activation module to the selection marker; (v) a dCas protein specifically recognizing the target sequence under the guidance of the guide RNA; and (vi) a screening cell. Also disclosed is a method for screening an RNA aptamer against a target protein using the system provided herein and RNA aptamers against S1 protein of SARS-CoV-2 virus and applications thereof.
Resumen de: WO2024133564A1
: SARS-CoV-2 spike protein-binding molecules are disclosed. Also disclosed are nucleic acids and expression vectors encoding, compositions comprising, and methods using, the SARS-CoV-2 spike protein-binding molecules.
Resumen de: WO2024137381A1
Disclosed are monoclonal antibodies, antigen binding fragments, and multi-specific antibodies that specifically bind a coronavirus spike protein, such as SARS-CoV-2. Also disclosed is the use of these antibodies and multi-specific antibodies for inhibiting a coronavirus infection, such as a SARS-CoV-2 infection. In addition, disclosed are methods for detecting a coronavirus, such as SARS-CoV-2, in a biological sample, using the disclosed antibodies and multi-specific antibodies. In some aspects, the antibodies bind a BA.4 or BA.5 variant. In other aspects, the antibodies bind BQ1.1 and/or XBV.
Resumen de: ZA202500860B
Provided are a pharmaceutical composition for resisting infection with SARS-CoV-2 or a mutant thereof, and a combined drug thereof. To solve the problem of the lack of effective prevention and treatment drugs for infection with SARS-CoV-2 or a mutant virus thereof, provided are a recombinant protein vaccine and/or an adenovirus vaccine for preventing and/or treating an infection with SARS-CoV-2 or a mutant thereof, and in particular, provided are a nasal spray administration compound formulation containing active ingredients of two vaccines, i.e., a recombinant protein vaccine and an adenovirus vaccine, and a combination of the two vaccines for nasal spray administration, which can induce generation of strong antibody and cellular immune responses in vivo and block the binding of a protein S of SARS-CoV-2 to an ACE2 receptor of a host cell, thus enabling a host to resist coronavirus infection. Particularly, the present invention has good prevention and treatment effects on various mutant viruses.
Resumen de: LU601360B1
A Chinese medicine formula for COVID-19, comprising the following raw materials by weight ratio: 25 grams of siraitia grosvenorii flower, 10 grams to 20 grams of ligustrum lucidum, 5 grams to 10 grams of winter mulberry leaves, 8 grams to 15 grams of Chinese mahonia, 5 grams to 10 grams of Dizhu leaves, 5 grams to 10 grams of gardenia jasminoides, 3 grams to 8 grams of astragalus membranaceus, 3 grams to 8 grams of gentiana, 5 grams to 10 grams of ophiopogon japonicus, 2 grams to 6 grams of cassia twig, 3 grams to 8 grams of artemisia argyi leaves, and 10 grams to 15 grams of hairy holly. Based on the in-depth analysis of the pathogenesis characteristics of COVID-19, the invention achieves a comprehensive improvement of the symptoms of the COVID-19 by reasonable compatibility of a variety of Chinese medicinal materials; wherein, the combination of siraitia grosvenorii flower and ligustrum lucidum significantly improves the symptoms of dry throat and cough; winter mulberry leaves and Chinese mahonia can synergistically reduce fever quickly; the invention is suitable for various symptoms such as headache, fever, sore throat, chest tightness, cough (dry cough) caused by the COVID-19; generally, it turns from positive to negative in 3 to 4 days, and it takes 5 days to 8 days to eliminate all the symptoms mentioned hereinabove, depending on the physical condition of each person.
Resumen de: US12453717B1
The present disclosure relates to a method of reducing or arresting viral load in a subject infected with a coronavirus, the method comprising the step of administering to the subject a therapeutically effective amount of a viral protease inhibitor. In some embodiments, the subject is a human. In one embodiment, the coronavirus is SARS-CoV-19 and the viral protease inhibitor is frovatriptan (6R)-6-(methylamino)-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide.
Resumen de: CN120842985A
The invention belongs to the technical field of antibacterial and antiviral materials, and particularly relates to a long-acting antibacterial and antiviral nano ceramic coating as well as a preparation method and application thereof. The nano ceramic coating provided by the invention comprises 25-30% of methoxytrimethylsilane, 1-5% of organosilicon quaternary ammonium salt, 20-30% of nano silicon dioxide sol, 0.5-1% of a catalyst, 1-2% of a protective agent, the balance of deionized water and the like. Compared with silver, copper, titanium and the like, the modified space is large, and compared with common quaternary ammonium salt materials, bacteria are not prone to evolving drug resistance. According to the invention, O-Si-O is taken as a main body to form a 3D net-shaped structure, through an anchor gun strategy, huge flexibility and a modification space are provided for a material structure, and efficient and rapid sterilization is realized. Tests on eight moulds and two viruses confirm that the nano ceramic coating belongs to a long-acting antibacterial and antiviral self-disinfection nano ceramic coating, and the mould resistance, enterovirus resistance and novel coronavirus resistance of the material are proved.
Resumen de: CN120842372A
The invention discloses a novel coronavirus neutralizing antibody, a detection kit and application of the novel coronavirus neutralizing antibody. The amino acid sequence of a heavy chain variable region of the neutralizing antibody is shown as SEQ ID No.1, and the amino acid sequence of a light chain variable region of the neutralizing antibody is shown as SEQ ID No.2. The antibody with mature affinity is screened through bioinformatics analysis of a single B cell, the antibody screening process is optimized by combining single cell RNA sequencing, VDJ rearrangement analysis and somatic cell hypermutation research, blindness of a traditional method is avoided, and the accuracy and effectiveness of antibody screening are improved. According to the neutralizing antibody GR39 provided by the invention, a heavy chain variable region and a light chain variable region of the neutralizing antibody GR39 can be specifically combined with an RBD structural domain of the SARS-CoV-2 and an S-Trimer structural domain of an Omicro variant, so that a broad-spectrum neutralizing effect on the SARS-CoV-2 virus and the variant thereof is realized. The binding activity of the antibody GR39 to S-Trimer and RBD under 2-fold and 300-fold dilution conditions is obviously superior to that of other antibodies, which indicates that the antibody GR39 has high affinity and dilution stability and is suitable for clinical large-dose administration.
Resumen de: CN120837599A
The invention provides a traditional Chinese medicine composition and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine. The traditional Chinese medicine composition capable of being used for treating novel coronavirus infection is obtained by taking Maxingshigan decoction and Yinqiao powder as the basis and simultaneously combining black nightshade herb, scourge-clearing toxin-vanquishing decoction, agastache rugosus stomach-clearing pills, vitex negundo-defatted toxin-vanquishing decoction, elsholtzia ciliata decoction, immature bitter orange, allium macrostemon and cassia twig decoction and magnolia flower rhinitis pills. The traditional Chinese medicine composition has the effects of resisting viruses, resisting inflammation and regulating immunity, and can inhibit virus replication in an extremely short time, so that the disease resistance of the body of a patient is quickly enhanced, and the body is completely recovered to be healthy and does not relapse.
Resumen de: CN120837493A
The invention discloses an application of a Fascin protein inhibitor in virus infection resistance. Specifically, the invention discloses an application of a small molecule drug NP-G2-044, and the small molecule drug NP-G2-044 is used for preparing a drug preparation or a composition for resisting virus infection. According to the NP-G2-044 disclosed by the invention, the formation of filopodia clamped by a virus is inhibited, so that the novel coronavirus is prevented from entering a host cell through the filopodia, and the virus infection is effectively controlled.
Resumen de: CN120842330A
The invention relates to a polypeptide RFTT and application of the polypeptide RFTT in preparation of a novel coronavirus resisting drug, belongs to the technical field of antiviral drugs, and provides the polypeptide RFTT, and the amino acid sequence of the polypeptide RFTT is HLYVSPWGGFLNRFTTTLNDFN; meanwhile, a cell-penetrating peptide sequence capable of penetrating cell membranes is added to the N end of the amino acid sequence of the polypeptide. The polypeptide can competitively inhibit phosphorylation of AKT-mediated new coronavirus main protease (Mpro), promote degradation of Mpro and inhibit virus replication. Besides, the polypeptide RFTT has the characteristics of strong target spot conservative property and high antiviral activity, and shows a remarkable new coronavirus variant resisting effect in an in-vitro Vero cell infection model, and the maximum median inhibitory concentration (IC50) for inhibiting replication of a new coronavirus wild strain is 0.034 mu M. Therefore, the polypeptide provided by the invention provides a new strategy for developing anti-new coronavirus drugs.
Resumen de: KR20250153936A
본 발명은 페이퍼 멤브레인 기반 현장 진단용 DNA 또는 RNA 추출 키트에 관한 것으로, 측방 유동 분리 방식을 기반으로, 짧은 시간 내에 효율적으로 다양한 종류의 샘플들로부터 DNA 또는 RNA 추출이 가능한 DNA 또는 RNA 추출 디바이스로서, 표적 바이러스 검출을 위한 페이퍼 멤브레인 기반 현장용 DNA 또는 RNA 추출 플랫폼을 제공할 수 있다.
Nº publicación: CN120858106A 28/10/2025
Solicitante:
INST OF MILITARY MEDICINE ACADEMY OF MILITARY SCIENCES OF PLA
\u4E2D\u56FD\u4EBA\u6C11\u89E3\u653E\u519B\u519B\u4E8B\u79D1\u5B66\u9662\u519B\u4E8B\u533B\u5B66\u7814\u7A76\u9662
Resumen de: CN120858106A
The invention discloses a short and small polypeptide capable of inhibiting beta human coronavirus from invading host cells in a broad-spectrum manner and a medicinal application of the short and small polypeptide. Reasonable drug design is carried out based on the universality and conservative property of the six-strand alpha-helix bundle (6-HB) structure of coronavirus spike protein in the process that beta human coronavirus enters host cells. According to the present invention, alpha helical conformation restriction is performed on an HR2 structure domain derived polypeptide in 6-HB, such that a short and small polypeptide having a broad-spectrum inhibition effect on infection of two or more beta human coronaviruses (such as SARS-CoV, MERS-CoV, SARS-CoV-2, OC43) is provided. The polypeptide has the important advantages of being high in antiviral activity, short in sequence, easy to synthesize and the like. Candidate drug reserve and technical reserve are proactively provided for research and development of emergency prevention and control drugs for new and reproduced human coronavirus infection epidemic situations in the future.
BOPI
Sede Electrónica
